Dose, Safety, and Pathogenicity of a New Influenza B Strain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-03

Study Completion Date

2024-02-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an exploratory study of an influenza B challenge strain to determine the optimum infectious titer of challenge agent in healthy participants 18 to 55 years of age.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain

NCT05572450

Influenza A H1N1

COMPLETED NA

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

NCT02350751

Influenza

COMPLETED PHASE1

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

NCT06907511

Pandemic Influenza Immunization Healthy Volunteers

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain

NCT06613737

Influenza A H3N2

COMPLETED NA

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

NCT06727058

Influenza Immunization

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an exploratory study of an influenza B challenge strain to determine the optimum safe infectious titer of challenge agent in healthy participants 18 to 55 years of age. A total of up to 80 participants may be given influenza B challenge virus. The study will be conducted in 2 parts. In Part A, 40 participants will be randomly allocated to one of two groups to be given one of two virus doses (Virus Dose 1 or Virus Dose 2). Based on the outcome of Part A, participants in Part B, may be given Virus Dose 1, Virus Dose 2, or another virus dose (e.g., Virus Dose 3).

Each participant will remain in the study for approximately 1 month from admission to quarantine to the last clinic visit.

The study is divided into three phases:

1. Screening phase: Screening will occur between Day -90 to Day -2/-1. has been signed by the participant.
2. Quarantine phase: Participants will stay in the quarantine unit for approximately 11 days (from Day -2/-1 to Day 8).

One or two days prior to the day of inoculation with the challenge virus, participants will be admitted to quarantine where their eligibility will be reassessed. If participants remain eligible for the study, they will receive the challenge virus on Day 0. Participants will undergo a range of clinical assessments and safety monitoring for the entirety of their stay in quarantine. Participants will be discharged from the quarantine unit on Day 8 (or may remain longer at the principal investigator's discretion).
3. Outpatient phase: Final follow-up visit 28 days (±3 days) after the day they receive the virus. Their symptoms will be reassessed, and a complete safety examination performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is an exploratory study of an influenza B challenge strain to determine the optimum infectious titer of challenge agent in healthy participants 18 to 55 years of age

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Participant and Investigator. Investigator will be blinded in Part A of the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A Dose Arm 1

Medium dose, expected to be approximately 10\^6 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)

Group Type EXPERIMENTAL

influenza B/Connecticut/1/21 virus part a dose arm 1

Intervention Type BIOLOGICAL

Medium dose, expected to be approximately 10\^6 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)

Part A Dose Arm 2

Dose Arm 2: High dose, expected to be approximately 10\^7 TCID50/ mL (titer may be adjusted based on stock titer)

Group Type EXPERIMENTAL

influenza B/Connecticut/1/21 virus part a dose arm 2

Intervention Type BIOLOGICAL

High dose, expected to be approximately 10\^7 TCID50/ mL (titer may be adjusted based on stock titer)

Part B Dose Extension:

Extension of one of the Part A dose arms; which one is to be determined (TBD) depending on outcome of Part A, AND/OR

Group Type EXPERIMENTAL

influenza B/Connecticut/1/21 virus part b dose 1

Intervention Type BIOLOGICAL

Extension of one of the Part A dose arms; which one is to be determined (TBD) depending on outcome of Part A, AND/OR Dose Arm 3

Part B Dose Arm 3

Addition of a 3rd dose, TBD depending on outcome of Part A

Group Type EXPERIMENTAL

influenza B/Connecticut/1/21 virus part b dose 2

Intervention Type BIOLOGICAL

Addition of a 3rd dose, TBD depending on outcome of Part A

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

influenza B/Connecticut/1/21 virus part a dose arm 1

Medium dose, expected to be approximately 10\^6 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)

Intervention Type BIOLOGICAL

influenza B/Connecticut/1/21 virus part a dose arm 2

High dose, expected to be approximately 10\^7 TCID50/ mL (titer may be adjusted based on stock titer)

Intervention Type BIOLOGICAL

influenza B/Connecticut/1/21 virus part b dose 1

Extension of one of the Part A dose arms; which one is to be determined (TBD) depending on outcome of Part A, AND/OR Dose Arm 3

Intervention Type BIOLOGICAL

influenza B/Connecticut/1/21 virus part b dose 2

Addition of a 3rd dose, TBD depending on outcome of Part A

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Adult male or female aged between 18 and 55 years
* A total body weight ≥50 kg and body mass index (BMI) ≥18 kg/m2 and ≤35kg/m2
* In good health with no history, or current evidence, of clinically significant medical conditions, and no clinically significant test abnormalities that will interfere with participant safety.
* Documented medical history
* Adherence to contraception requirements
* Serosuitable for the challenge virus.

Exclusion Criteria

* History of, or currently active, symptoms or signs suggestive of upper or lower respiratory tract (LRT) infection within 4 weeks prior to the first study visit.
* Any history or evidence of any clinically significant or currently active disease.
* Any participants who have smoked ≥10 pack years at any time.
* Female participants who are breastfeeding, or have been pregnant within 6 months prior to the study, or have a positive pregnancy test at any point during screening or prior to inoculation.
* Lifetime history of anaphylaxis and/or a lifetime history of severe allergic reaction.
* Venous access deemed inadequate for the phlebotomy and cannulation demands of the study.
* Significant abnormality of the nose, epistaxis, nasal or sinus surgery.
* Recent vaccinations or intention to receive vaccination before the final follow up visit.
* Receipt of blood or blood products, or loss (including blood donations) of 550 mL or more of blood during the 3 months prior to the planned inoculation or planned during the 3 months after the final visit.
* Recent receipt of investigational drugs or challenge viruses.
* Use or anticipated use during the conduct of the study of concomitant medications (prescription and/or non-prescription), including vitamins or herbal and dietary supplements within the specified windows.
* Positive drugs of abuse test or recent history or presence of alcohol addiction
* A forced expiratory volume in 1 second (FEV1) \<80%.
* Positive HIV, hepatitis B virus, or hepatitis C virus test.
* Presence of fever, defined as participant presenting with a temperature reading of ≥37.9C on Day -2/-1 and/or pre-inoculation on Day 0.
* Those employed or immediate relatives of those employed at hVIVO or the sponsor.
* Any other reason, in the opinion of the investigator deems the participant unsuitable for the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes